Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy

Introduction: Data regarding the efficacy of anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) messenger RNA vaccines in immunocompromised hosts are scarce and no data yet appear to be available for patients with hematological malignancies who also received chimeric antigen receptor-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gastinne, Thomas, Le Bourgeois, Amandine, Coste-Burel, Marianne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Imbert, Berthe-Marie, Drumel, Thomas, Mahé, Béatrice, Dubruille, Viviane, Blin, Nicolas, Lok, Anne, Touzeau, Cyrille, Tessoulin, Benoit, Jullien, Maxime, Vantyghem, Sophie, Bene, Marie C, Moreau, Philippe, Le Gouill, Steven, Chevallier, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
704.Cellular Immunotherapies: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701699/
http://dx.doi.org/10.1182/blood-2021-149476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701699/
http://dx.doi.org/10.1182/blood-2021-149476

Ejemplares similares